CBD & safety
CBD absorption, food effects and metabolism: why milligrams matter
Understand oral bioavailability, high-fat food effects, CYP enzymes, metabolites and why a 50 ml bottle is not a dose.
Controlled pharmacokinetic work shows large food effects and dose-dependent exposure. The Enki bottle strength and route must be confirmed from its current label before any use decision.
Compounds & molecular formulae
CBD
C₂₁H₃₀O₂
Lipophilic and extensively metabolised; an oral dose is not equivalent to the same amount placed on skin.
PubChem compound record ↗7-carboxy-CBD
C₂₁H₂₈O₄
The major circulating metabolite in a Phase I oral pharmacokinetic study.
PubChem compound record ↗Exposure (AUC) = ∫ concentration(t) dt
Area under the concentration–time curve summarises systemic exposure. It is not a measure of clinical benefit by itself.
mg CBD per mL = total CBD in bottle (mg) ÷ bottle volume (mL)
This simple label calculation is why a 50 ml volume should be accompanied by total CBD in milligrams and a verified serving direction.
What the Phase I data show
A randomised Phase I study of highly purified oral CBD tested single doses of 1,500–6,000 mg and multiple doses of 750 or 1,500 mg twice daily in healthy adults [1]. CBD appeared in plasma with a time to maximum concentration of about four to five hours, and 7-carboxy-CBD was the major circulating metabolite. Exposure increased less than proportionally with dose. These are pharmacokinetic observations at very high, defined doses—not a recommendation for a retail product.
Food can change exposure dramatically
In the same Phase I work, a high-fat meal increased CBD maximum concentration about 4.85-fold and exposure about 4.2-fold [1]. A separate capsule study in adults with refractory epilepsy found average fed-state Cmax about 14 times fasting and AUC about four times fasting [2]. The exact size of a food effect depends on formulation and study conditions, but the principle is important: taking a lipophilic product with a meal can change exposure. Consistency and clinician guidance matter more than guessing from a dropper.
Metabolism and interactions
CBD is metabolised by hepatic enzymes, and prescription labeling warns about dose-related liver-transaminase elevations and interactions. Inhibiting or inducing CYP2C19, CYP3A4 or other pathways can change concentrations of CBD or co-medications; CBD can also alter other drugs. A customer taking anti-epileptics, anticoagulants, sedatives, immunosuppressants or multiple medicines should ask a clinician or pharmacist before using a cannabinoid product. Do not stop a prescribed medicine because a blog or chat assistant mentions a pathway.
The label questions to ask Enki
Request total CBD per bottle, CBD per ml or stated serving, THC result, ingredient concentrations, route, storage and a batch report. Enki currently lists a 50 ml bottle and describes peppermint, rosemary and sunflower oil in the blend; the exact ratios and cannabinoid strength are not inferred here. Do not treat the product’s volume, an internet dose table or a prescription label as interchangeable information.
Sources & credits
- Taylor et al. Phase I safety, tolerability and pharmacokinetics of highly purified cannabidiol (CNS Drugs, 2018) — Phase I pharmacokinetic trial
- Birnbaum et al. Food effect on pharmacokinetics of cannabidiol oral capsules (Epilepsia, 2019) — Human food-effect study
- FDA: EPIDIOLEX prescribing information — Prescription-label safety and interaction context